Compromised Immunologic Recovery in Treatment-Experienced Patients with HIV Infection Receiving Both Tenofovir Disoproxil Fumarate and Didanosine in the TORO Studies | Zendy

Eugènia Negredo | Zendy; Anna Bonjoch | Zendy; Roger Paredes | Zendy; Jordi Puig | Zendy; Bonaventura Clotet | Zendy

Open Access

Compromised Immunologic Recovery in Treatment-Experienced Patients with HIV Infection Receiving Both Tenofovir Disoproxil Fumarate and Didanosine in the TORO Studies

Author(s) -

Eugènia Negredo,

Anna Bonjoch,

Roger Paredes,

Jordi Puig,

Bonaventura Clotet

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/432879

Subject(s) - didanosine , medicine , tenofovir , regimen , human immunodeficiency virus (hiv) , clinical trial , immunology , virology , viral disease , sida

The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research